Powder: -20°C for 3 years | In solvent: -80°C for 1 year
BAY-985 is a potent, selective, and orally active ATP-competitive dual inhibitor of TBK1 and IKKε (IC50s: 2/30 and 2 nM for TBK1 (low/high ATP) and IKKε) with antitumor efficacy.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
1 mg | 在庫あり | ¥ 40,500 | |||
5 mg | 在庫あり | ¥ 85,500 | |||
10 mg | 在庫あり | ¥ 137,000 | |||
25 mg | 在庫あり | ¥ 219,000 | |||
50 mg | 在庫あり | ¥ 296,000 | |||
100 mg | 在庫あり | ¥ 397,000 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 104,000 |
説明 | BAY-985 is a potent, selective, and orally active ATP-competitive dual inhibitor of TBK1 and IKKε (IC50s: 2/30 and 2 nM for TBK1 (low/high ATP) and IKKε) with antitumor efficacy. |
ターゲット&IC50 | TBK1:2 nM (low ATP), TBK1:30 nM (high ATP), IKKε:2 nM |
In vitro | BAY-985 inhibits FLT3, RSK4, DRAK1, and ULK1 (IC50s: 123, 276, 311, and 7930 nM). BAY-985 inhibits the cellular phosphorylation of interferon regulatory factor 3 (IRF3, IC50: 74 nM). BAY-985 shows anti-proliferative activity in a few cancer cell lines (IC50s: 900 and 7260 nM for SK-MEL2 (NRAS and TP53 mutated) and ACHN (CDKN2A mutated) cells). |
In vivo | BAY-985 (200 mg/kg; p.o.; b.i.d.; 111 days) results in weak antitumor efficacy. BAY-985 shows high clearance (CLb= 4.0 L/h/kg, ca. 95% hepatic extraction), large volume of distribution at steady state (Vss=2.9 L/kg) and a short terminal half-life (t1/2=0.79 h). |
分子量 | 553.58 |
分子式 | C27H30F3N9O |
CAS No. | 2409479-29-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/mL (90.32 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
BAY-985 2409479-29-2 NF-Κb IκB/IKK BAY 985 BAY985 IKK IκB kinase melanoma IKKε TBK1 inhibit I kappa B kinase Inhibitor antitumor inhibitor